Harnessing the Potential of Molecular Pathology

Back to overview page

The rapidly evolving field of molecular pathology holds tremendous potential to advance therapeutic approaches in precision medicine. Cutting-edge technology and developments in molecular testing and diagnostics are revolutionizing the way diseases are diagnosed and treated. Harnessing the potential of molecular insights enables effective personalized therapies that are shaping the future of patient care.


Unlock molecular insights from myeloid neoplasms

Molecular monitoring underpins the characterization and management of myeloid neoplasms. Genomic characterization provides crucial information for accurate diagnosis, risk assessment, therapeutic decision-making, residual disease monitoring, progression, and treatment resistance. While conventional cytogenetics is the cornerstone for diagnostic evaluation, advances in genomic techniques are unraveling the genetic alterations underlying these hematological malignancies.

Next-generation sequencing (NGS) is pivotal in molecular testing of myeloid neoplasms. Proper risk stratification and patient management relies on analysis of a continuously increasing number of alterations. Harnessing the power of NGS to identify these genetic alterations and actionable biomarkers paves the way for improved diagnosis, prognosis, and management of patients as well as development of targeted therapies.


The transformative power of AI in molecular medicine

The potential of AI in the context of multi-drug resistant (MDR) bacterial infections is a hot topic. As the incidence and complexity of MDR infections are continuously increasing, there is an urgent need for novel approaches to tackle the threat of these infections and combat the global spread. AI and machine learning demonstrate significant potential for analysis and interpretation of the massively complex datasets generated by emerging approaches. This is reflected in the adoption of NGS and machine learning to predict antimicrobial resistance. AI is also playing an important role in phage biology to advance development of therapeutics for treatment of MDR infections and to combat antimicrobial resistance.


Promise of minimal/molecular residual disease testing in cancer

Detection of minimal/molecular residual disease (MRD) is a powerful tool in hematological malignancies and solid tumors. MRD refers to the small number of cancer cells remaining in the body after cancer treatment. Monitoring of MRD is important to assesses treatment response, identify patients with an increased risk of relapse, and guide treatment decisions.

First used in hematological malignancies, MRD detection is becoming more widely used to predict future relapse risk in a number of other cancers. The number of technologies used for MRD detection is continuously growing – from flow cytometry and qPCR to dPCR and NGS and beyond. New techniques and algorithms are enhancing the prognostic and predictive value of MRD detection.

However, there is still some way to go to overcome the hurdles of assay sensitivity, standardization, and the complexity of data interpretation.


We can integrate automation into your molecular pathology workflows

Our deep understanding of medical and biological applications enables the analysis of biological workflows in terms of chemistry, consumables, equipment, and software. Our world-class engineers and scientists understand the unique requirements and complex nature of biological and medical applications and develop automated systems according to ISO 13485.

Our expertise covers a wide range of technologies, such as:

  • Automated sample prep using magnetic beads or spin columns
  • Quality control using capillary electrophoresis or optical analysis
  • NGS and qPCR analysis
  • Statistics, ML/AI, signal processing, computer vision and more

In this way, we bridge the knowledge gap between biology and engineering expertise, creating customized solutions that are an optimal fit for your applications.


Schedule a meeting with us at the AMP 2024 Europe Congress

We will attend the AMP 2024 Europe Congress and are keen to engage with other attendees. If you want to explore cutting-edge automation that can transform your molecular pathology workflows, join us and gain valuable insights into the latest technological breakthroughs. Take advantage of this unparalleled opportunity and make an appointment in advance to meet with our expert, Patrick Widler (CCO).

Let’s collaborate and shape the future of diagnostics and patient care together.


Patrick Widler

Touch Base with us

Successful automation of life science and diagnostics workflows is a highly complex undertaking. With our key technology and application knowledge as well as with our high level of experience we will help you to shorten your time-to-market and grow your business.